Engineering dendritic cell vaccines to improve cancer immunotherapy.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31776331.
- Also identified by DOI 10.1038/s41467-019-13368-y and PMC identifier 6881351.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
At the interface between the innate and adaptive immune system, dendritic cells (DCs) play key roles in tumour immunity and hold a hitherto unrealized potential for cancer immunotherapy. Here we review the role of distinct DC subsets in the tumour microenvironment, with special emphasis on conventional type 1 DCs. Integrating new knowledge of DC biology and advancements in cell engineering, we provide a blueprint for the rational design of optimized DC vaccines for personalized cancer medicine.
Medical subject headings
- Cancer Vaccines
- Dendritic Cells
- Immunotherapy